US Patent 9907767 Pharmaceutical compositions and the treatment of overactive bladder
Patent 9907767 was granted and assigned to Velicept Therapeutics on March, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 2 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Article (+549 characters)
Article
Patent abstract
The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
Edits on 1 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Eliot Ohlstein0
Stephen Caltabiano0
Stewart McCallum0
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09907767 Pharmaceutical compositions and the treatment of overactive bladder US Patent 9907767 Pharmaceutical compositions and the treatment of overactive bladder
Infobox
Patent Number
09907767
Patent Number
9907767
Edits on 19 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09907767 Pharmaceutical compositions and the treatment of overactive bladder
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09907767
Date of patent
March 6, 2018
Patent application number
15323685
Date Filed
January 3, 2017
Patent primary examiner
Find more entities like US Patent 9907767 Pharmaceutical compositions and the treatment of overactive bladder
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
